¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18
±³À°ÀÏÀÚ : 2021-09-18
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ  
´ã´çÀÚ : ¹éÁöÀº
¿¬¶ôó : 02-3275-5335  
À̸ÞÀÏ : kshf4@kshf.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í ±³¼ö: 70,000¿ø, ÀϹÝÀÇ: 30,000¿ø, Àü°øÀÇ, °£È£»ç, 65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:00~10:30 Optimal HFrEF Treatment, New Perspectives  James Januzzi(Harvard University USA) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:30~11:00 Role of SGLT2I from Chronic to Acute HF, Where Is Proper Position in GDMT?  Michael Bohm(Saarland University Germany) 
Åä·Ð 09-18 ±×·£µåº¼·ë 11:00~11:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 11:20~11:30 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:30~11:45 Smartphone Application for Cardiac Rehabilitation: Strength and Weakness  ±èÀÀÁÖ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:45~12:00 Skeletal Muscle and Prognosis of HF: Can Cardiac Rehabilitation Overcome Muscle Wasting?  Kazunori Shimada(Juntendo University Hospital Japan) 
Åä·Ð 09-18 ±×·£µåº¼·ë 12:00~12:10 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
½Ä»ç 09-18 ±×·£µåº¼·ë 12:10~13:00 Lunch  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:00~13:50 Brigntening Abstract Presentation (II)  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:50~14:10 Challenge of Prescribing Inertia: from CHAMP-HF Registry  Biykem Bozkurt(Baylor College of Medicine HoustonTX) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:10~14:25 Performance Measures for HF Management in Korea  À±Á¾Âù(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:25~14:45 Benefits of Quadruple Therapy for HFrEF  JoAnn Lindenfeld(Vanderbilt University Medical Center Nashville TN) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:45~15:00 Comprehensive or Stepwise Treatment for HFrEF  ÃÖÁ¤Çö(ºÎ»êÀÇ´ë) 
Åä·Ð 09-18 ±×·£µåº¼·ë 15:00~15:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 15:20~15:30 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:20~15:35 Benefit of SGLT2 Inhibitors across the Cardiorenal Continuum  ±ÇÇõ»ó(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:35~15:50 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Non-cardiac effect  ÃÖ¼ºÈñ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:50~16:05 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Cardiac Effect  Á¶Àͼº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 16:05~16:20 Positioning of SGLT2 Inhibitors in HF Management: How Should We Sequence?  John McMurray(Univ of Glasgow. UK) 
Åä·Ð 09-18 ±×·£µåº¼·ë 16:20~16:50 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 16:50~17:00 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:00~17:15 Ischemic Cardiomyopathy  Yuhui Zhang(CHFA China) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:15~17:30 Idiopathic Dilated Cardiomyopathy  ÀÌ»ó¾ð(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:30~17:45 Acute and Chronic Myocarditis  Jian Zhang(CHFA China) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:45~18:00 Hypertrophic Cardiomyopathy  ±èÀÎö(°è¸íÀÇ´ë) 
Åä·Ð 09-18 ±×·£µåº¼·ë 18:00~18:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó)  

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ (¿Â¶óÀÎ) Á¦58Â÷ ¾Ë·¹¸£±â ±³À°°­Á : 2021-09-25
´ÙÀ½±Û ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 2ÀÏÂ÷ : 2021-09-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20590 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 14ÀÏ ±Ý¿äÁý´ãȸ(¸¸¼º ºÎºñµ¿¿°ÀÇ Ä¡·á) : 2024-06-14 0 2 2024-04-29
20589 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GI Cancer 2024 : 2024-06-14 0 3 2024-04-29
20588 ¼­¿ï ´ëÇÑ°ñ´ë»çÇÐȸ SSBH 2024 (The 12th Seoul Symposium on Bone Health)&Á¦36Â÷ Ãá°èÇмú´ëȸ 2ÀÏÂ÷ : 2024-06-14 0 1 2024-04-29
20587 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 2ÀÏÂ÷ : 2024-06-14 0 1 2024-04-29
20586 °æºÏ 2024 ´ëÇÑÆó¾ÏÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-14 0 2 2024-04-29
20585 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 1ÀÏÂ÷ : 2024-06-13 0 0 2024-04-29
20584 ¼­¿ï ´ëÇÑ°ñ´ë»çÇÐȸ SSBH 2024 (The 12th Seoul Symposium on Bone Health)&Á¦36Â÷ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-06-13 0 1 2024-04-29
20583 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-ÃÖ½ÅÇü º¸Ã»±â¿Í ¸ÂÃãÇü º¸Ã»±â ó¹æ¿ä·É : 2024-06-13 0 1 2024-04-29
20582 ¼­¿ï °­³²¼¼ºê¶õ½º ¾È°ú Áö¿ªÀÇ»çÁý´ãȸ(³­Ä¡¼º °¢¸· Áúȯ) : 2024-06-11 0 1 2024-04-29
20581 ¼­¿ï [¿Â¶óÀÎ] Á¦274ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸ(Æó±â´É°ú ±â°üÁö°ú¹Î¼º) : 2024-06-11 0 3 2024-04-29
20580 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø [¿Â¶óÀÎ] Á¦ 26 ȸ ¿Ü·¡Â÷¿øÀÇ ¼Ò¾Æû¼Ò³â°ú ÀÓ»ó : 2024-06-09 0 2 2024-04-29
20579 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø ¼øȯ±â³»°ú 16ȸ KOALA Symposium 2024 : 2024-06-09 0 1 2024-04-29
20578 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ (¿Â¶óÀÎ) Á¦3ȸ ¼ö¸é°øµ¿½ÉÆ÷Áö¾ö : 2024-06-09 0 2 2024-04-29
20577 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ 2024 ´ç´¢º´ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-09 0 2 2024-04-29
20576 ¼­¿ï 2024 ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-08 0 5 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷